CASSAVA SCIENCES INC

SAVA Nasdaq CIK: 0001069530

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, 78731
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, 78731
Phone 512-501-2444
Fiscal Year End 1231
EIN 911911336

Financial Overview

FY2024

$14.20M
Total Liabilities
$253.91M
Stockholders' Equity
$128.57M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events December 23, 2025 View on SEC
8-K/A Current report amendment December 22, 2025 View on SEC
8-K Current report of material events December 18, 2025 View on SEC
8-K Current report of material events December 17, 2025 View on SEC
424B2 Prospectus for shelf offering December 5, 2025 View on SEC
8-K Current report of material events December 3, 2025 View on SEC
4 Insider stock transaction report November 25, 2025 View on SEC
4 Insider stock transaction report November 24, 2025 View on SEC
4 Insider stock transaction report November 20, 2025 View on SEC
S-3 Shelf registration for future offerings November 13, 2025 View on SEC

Material Events

8-K Legal Issue December 23, 2025
High Impact
  • Cassava Sciences Inc. settled a major class-action lawsuit for $31.25 million, resolving claims of violating federal securities laws.
  • The settlement removes a significant legal cloud and uncertainty that had been hanging over the company.
View Analysis
8-K Legal Issue December 18, 2025
High Impact
  • The U.S. Food and Drug Administration (FDA) has placed a "full clinical hold" on Cassava Sciences' planned study for simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy.
  • The FDA requires Cassava Sciences to provide more information, including additional lab data, and to change the planned study design before it can proceed.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.